{
    "nctId": "NCT03917381",
    "briefTitle": "GEN1046 Safety Trial in Patients With Malignant Solid Tumors",
    "officialTitle": "First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 429,
    "primaryOutcomeMeasure": "Dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\nFor Dose Escalation:\n\n\u2022 Have a histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy\n\nFor Expansion:\n\n\u2022 Have histologically or cytological confirmed diagnosis of relapsed or refractory, advanced and/or metastatic NSCLC, EC, UC, TNBC, SCCHN, or cervical cancer who are not anymore candidates for standard therapy For separate expansion cohorts: metastatic NSCLC without prior systemic treatment regimens for metastatic disease.\n\nFor Both Dose Escalation and Expansion\n\n* Have measurable disease according to RECIST 1.1\n* Have Eastern Cooperative Oncology Group (ECOG) 0-1\n* Have an acceptable hematological status\n* Have acceptable liver function\n* Have an acceptable coagulation status\n* Have acceptable renal function\n\nKey Exclusion Criteria:\n\n* Have uncontrolled intercurrent illness, including but not limited to:\n\n  * Ongoing or active infection requiring intravenous treatment with anti-infective therapy, or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.\n  * Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris or cardiac arrhythmia\n  * Uncontrolled hypertension defined as systolic blood pressure \u2265 160 mmHg and/or diastolic blood pressure \u2265 100 mmHg, despite optimal medical management\n  * Ongoing or recent evidence of autoimmune disease\n  * History of irAEs that led to prior checkpoint treatment discontinuation\n  * Prior history of myositis, Guillain-Barr\u00e9 syndrome, or myasthenia gravis of any grade\n  * History of chronic liver disease or evidence of hepatic cirrhosis\n  * History of non-infectious pneumonitis that has required steroids or currently has pneumonitis\n  * History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of acasunlimab\n  * Serious, non-healing wound, skin ulcer (of any grade), or bone fracture\n* Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new (younger than 6 months) or progressive brain metastases or stroke\n* Prior therapy:\n\n  * Radiotherapy within 14 days prior to first dose of acasunlimab. Note: palliative radiotherapy will be allowed.\n  * Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to acasunlimab administration. Accepted exceptions are bisphosphonates (e.g., pamidronate, zoledronic acid, etc.) and denosumab\n* Toxicities from previous anti-cancer therapies that have not adequately resolved\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}